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Abstract
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection
for stage III colon cancer has been shown to improve both progression-free and overall survival, and is currently
recommended as standard therapy. However, its value for patients with stage II disease remains controversial.
When this study was designed 5-fluorouracil (5FU) plus leucovorin (LV) was standard adjuvant treatment for colon
cancer. Irinotecan (CPT-11) is a topoisomerase I inhibitor with activity in metastatic disease. In this multicenter
adjuvant phase III trial, we evaluated the addition of irinotecan to weekly 5FU plus LV in patients with stage II or III
colon cancer.
Methods: The study included 873 eligible patients. The treatment consisted of weekly administration of irinotecan
80 mg/m
2 intravenously (IV), LV 200 mg/m
2 and 5FU 450 mg/m
2 bolus (Arm A) versus LV 200 mg/m
2 and 5FU 500
mg/m
2 IV bolus (Arm B). In Arm A, treatments were administered weekly for four consecutive weeks, followed by a
two-week rest, for a total of six cycles, while in Arm B treatments were administered weekly for six consecutive
weeks, followed by a two-week rest, for a total of four cycles. The primary end-point was disease-free survival (DFS)
at three years.
Results: The probability of overall survival (OS) at three years was 0.88 for patients in Arm A and 0.86 for those in
Arm B, while the five-year OS probability was 0.78 and 0.76 for patients in Arm A and Arm B, respectively (P =
0.436). Furthermore, the probability of DFS at three years was 0.78 and 0.76 for patients in Arm A and Arm B,
respectively (P = 0.334). With the exception of leucopenia and neutropenia, which were higher in patients in Arm
A, there were no significant differences in Grades 3 and 4 toxicities between the two regimens. The most
frequently recorded Grade 3/4 toxicity was diarrhea in both treatment arms.
Conclusions: Irinotecan added to weekly bolus 5FU plus LV did not result in improvement in disease-free or
overall survival in stage II or III colon cancer, but did increase toxicity.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12610000148077
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Colorectal cancer is one of the world’s most common
malignancies. After lung cancer, it is the most frequent
cause of cancer-related mortality in the Western
World [1]. Despite curative surgery in those presenting
early, the risk of recurrence is significantly high with a
mortality rate still close to 40%. Hence, much work
has been done in search of effective adjuvant therapy
for the eradication of disseminated micrometastases. In
colon cancer, chemotherapy is the principal adjuvant
therapy and the addition of radiotherapy to che-
motherapy has not been shown to improve outcome
[2]. In the absence of any further treatment after resec-
tion of the primary tumor, five-year survival rates are
principally determined by the stage of the tumor at the
time of resection. Studies performed in the late 1980s
demonstrated that adjuvant fluorouracil (5FU) plus
levamisole improved survival in patients with a
resected stage III colon cancer. Further studies per-
formed in the mid-1990s established 5FU plus leucov-
orin (LV) administered for approximately six months
as a standard postoperative treatment. The therapeutic
potential of systemic treatments for colorectal cancer
has expanded rapidly during the past 10 years, with
the introduction of oral fluoropyrimidines, oxaliplatin,
and irinotecan [3-6].
Irinotecan is a topoisomerase I inhibitor with activity
in metastatic colorectal cancer, alone or in combina-
tion with other agents [7,8], in both first- and second-
line treatment of metastatic disease [9-13]. Cunning-
ham et al. [ 1 4 ]r a n d o m i z e d ,i na2 : 1r a t i o ,p a t i e n t s
with metastatic colorectal cancer, which had pro-
gressed within six months of treatment with 5FU to
receive either irinotecan with supportive care or sup-
portive care alone and demonstrated a one-year survi-
val rate 2.5 times greater for the irinotecan group than
that achieved with best supportive care alone. Two
further randomized trials of first-line therapy using iri-
notecan with or without 5FU plus LV demonstrated
statistically significant survival advantages for the com-
bination regimen [15,16]. As a result, the weekly irino-
tecan plus 5FU plus LV regimen became standard for
first-line metastatic colorectal cancer. The improve-
ments in response rate, progression-free survival (PFS),
and overall survival (OS) achieved with the incorpora-
tion of irinotecan in the systemic treatment of patients
with metastatic colorectal cancer encouraged its testing
in the adjuvant setting, especially in patients with stage
III disease. We performed a randomized controlled
trial of the combination of weekly irinotecan plus LV
plus 5FU versus a standard weekly schedule 5FU plus
LV in the adjuvant setting following curative resection
of stage II and III colon cancer.
Methods
Patient selection
All eligible patients had histologically confirmed colon
adenocarcinoma and underwent complete surgery for
stages B2 and C disease with neither gross nor micro-
scopic evidence of residual tumor. The patients entered
the study within three to six weeks after surgery; had
not received any prior chemotherapy; were aged at least
18 years; had a World Health Organization (WHO) per-
formance status ≤2; and should have no history of other
malignancies except of adequately treated carcinoma in
situ of the uterine cervix, or curatively treated non-mel-
anomatous skin cancer or serious illness that would pre-
clude protocol chemotherapy. Other laboratory
eligibility requirements included absolute neutrophil
count ≥1,500/μl, platelet count ≥100,000/μl, serum crea-
tinine <1.5 mg/dl, and alanine transaminase (ALT) and
aspartate aminotransferase (AST) levels less than twice
the institutional upper limit of normal. Non eligibility
criteria were histology other than adenocarcinoma,
incomplete resection, myocardial infarction within the
last six months or uncontrolled coronary insufficiency,
inflammatory intestinal disease, and pregnant or nursing
women. The clinical protocol and collateral translational
studies were approved by the Hellenic Cooperative
Oncology Group (HeCOG) Protocol Review Committee.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and Good
Clinical Practice. Our study was also registered at the
Australian New Zealand Clinical Trials Registry
(ACTRN12610000148077). Before randomization all
patients provided written informed consent and eligibil-
ity was confirmed by a protocol-specific checklist.
Evaluation
Before study entry, all patients underwent a complete
physical examination, assessment of performance status,
complete blood cell (CBC) count and differential, liver
and kidney function tests, serum carcinoembryonic anti-
gen (CEA) and cancer antigen (CA) 19-9, urinalysis,
electrocardiogram (ECG), pelvic and abdominal com-
puted tomography, and chest X-ray with computed
tomography of the chest when clinically indicated. Dur-
ing treatment, clinical evaluation and CBC were per-
formed every week. Furthermore, biochemistry
laboratory evaluations were performed every two weeks
until the end of the treatment, and then every three
months thereafter. Abdominal and pelvic CT scans and
chest-X-ray were performed at the end of the study, and
then every six months thereafter. However, CT scans
were repeated earlier whenever clinically indicated
depending on the discretion of the investigator. Endo-
scopy was performed annually [12,17].
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Eligible and registered patients were randomly assigned
using central registration to receive either irinotecan
plus LV plus 5FU (Arm A) or LV plus 5FU (Arm B).
Chemotherapy in Arm A consisted of irinotecan 80 mg/
m
2 in 250 ml normal saline, as a 90-minute intravenous
(IV) infusion, followed by LV 200 mg/m
2 in 500 ml nor-
mal saline, IV over two hours, and 5FU 450 mg/m
2,a s
IV rapid administration, 60 minutes after initiation of
LV infusion. Treatments were administered weekly for
four consecutive weeks, followed by a two-week rest, for
a total of six cycles. The LV plus 5FU group (Arm B)
received chemotherapy consisting of LV 200 mg/m
2 by
IV injection over two hours, with a bolus of 5FU
500 mg/m
2 administered by IV injection at 60 minutes
after initiation of LV. Treatments were administered
weekly for six consecutive weeks, followed by a two-
week rest, for a total of four cycles.
Dose modification
Toxicities were graded using the WHO common cri-
teria. Dose adjustments of the drugs or treatment delays
were decided according to the worst toxicity grade at
preceding cycle. The dose modification was determined
according to the body system showing the greatest toxi-
city. Chemotherapy was interrupted if Grade more than
2 toxicity was encountered and was restarted when toxi-
city had resolved to ≤Grade 1. In case of diarrhea, the
patients underwent supportive care and also intensive
treatment with loperamide and were hospitalized if
necessary. The doses of irinotecan and 5FU were
reduced by 20% or 30% in the case of Grades 2 and 3
diarrhea, respectively. In the presence of Grades 1, 2
and 3 hematological toxicity, treatment was delayed for
at least one week until hematological recovery without
dose reductions in further infusions, while in the case of
Grade 4 hematological toxicity, irinotecan as well as the
5FU dose was reduced by 20% in all the subsequent
courses.
There was no re-escalation for patients experiencing
bone marrow or gastrointestinal toxicity requiring dose
modification. In the case of hand-foot syndrome (Grade
3 or 4), only the dose of 5FU was to be reduced by 20%.
In the case of angina or myocardial infarction the treat-
ment would be ceased. Furthermore, for Grade 3 or
4 mucositis, there was a possibility for restarting the
treatment after one week delay, if toxicity had resolved
to ≤Grade 1 and the dose of irinotecan and 5FU was to
be reduced by 20%. In the presence of any Grade 4 toxi-
city, except for gastrointestinal or hematological toxicity,
the patients were withdrawn from the study. No prophy-
lactic treatment was permitted for diarrhea. Specific
guidelines for curative treatment of delayed diarrhea
were provided, which recommended loperamide 2 mg
every 2 h for 12 h after the last loose stool, for a maxi-
mum of 48 consecutive hours. If diarrhea was not con-
trolled after 48 h of non-stop loperamide intake, or if
the patient was dehydrated, loperamide was stopped and
the patient was hospitalized for intravenous fluids.
Statistical analysis
For a two-sided test at the 5% level of significance and a
power of 80%, the number of patients required to detect
a difference between the two treatment arms within 5%
(± 2.5%) to the baseline rate of 80% in DFS at the three-
year time point [18] was 870 patients. Taking into
account a 3% withdrawal, 900 patients (450 per group)
were needed to enter the study with an accrual rate of
170 patients per year and a corresponding maximum
study duration of 9.9 years. An interim analysis based
on the O’Brien Fleming boundary values was performed
when half (50%) of the endpoints (161 relapses) had
been reached. The study would be ended prematurely if
either a significant difference was detected or the alter-
native was rejected at the interim analysis. No signifi-
cant difference in DFS rate was detected (P = 0.112) and
the study was continued to completion.
Overall survival (OS) was measured from the date of
randomization until death from any cause. Surviving
patients were censored at the date of last contact. DFS
was measured from the date of randomization until
recurrence of tumor or secondary malignancy or death
from disease without relapse. “Secondary malignancy”
includes any cancer and not just another colorectal can-
cer. Death from disease without relapse means death
without documented progression of the disease, which
includes deaths from any cause.
Continuous variables were presented as medians with
the corresponding range and categorical variables as fre-
quencies with the respective percentages. The Fisher’s
exact test and the non-parametric Mann-Whitney were
used for comparing patient and tumor characteristics.
Time to event distributions were estimated using
Kaplan-Meier curves and compared using the log-rank
test. The Cox proportional hazards models were used to
assess the relationship of OS and DFS with various clini-
cal and histological variables. The backward selection
procedure with removal criterion P >0.10 based on Like-
lihood ratio test was performed to identify significant
variables among the following: treatment group (Arm A
versus Arm B), age, histology grade (I versus II to III),
Dukes stage (B versus C), number of examined lymph
nodes, number of involved lymph nodes, obstruction
(no versus yes), perforation (no versus yes), primary site
(right colon versus left colon versus sigmoid). All statisti-
cal tests were two-sided and performed at a significance
level of 0.05. The SPSS software was used for statistical
analysis (SPSS for Windows, version 18.0 PASW
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following the modified intention-to-treat principle, that
is, including all eligible patients.
Results
Between January 1999 and September 2004, 909 patients
were randomly assigned to irinotecan plus 5FU plus LV
or to 5FU plus LV. Thirty-six patients (4%) were ineligi-
ble: 15 had metastatic disease, 11 had rectal cancer,
5 had non radical surgery, 3 had a history of other
malignancy, 1 had positive margins, and 1 had ovarian
adenocarcinoma. The outline of the study is shown
in Figure 1. For 14 patients medical records were
incomplete at the time of the analysis (8 from Arm
A and 6 from Arm B). Furthermore, six patients in Arm
A and eight patients in Arm B never started on che-
motherapy; these patients were included in the efficacy
analysis according to the intent-to-treat method, but
were excluded from the toxicity and treatment charac-
teristics analyses. Four patients randomized to Arm A
received Arm B treatment and vice versa. Patient char-
acteristics were well balanced for age, gender, T and N
stage, median number of nodes reported, and the pre-
sence of perforation or obstruction (Table 1).
Out of the 873 eligible patients, 148 discontinued
treatment, 77 (18%) patients in Arm A and 71 (17%) in
RANDOMIZATION
Randomized n=909 
Eligible n=873 
Arm A: LV + 5FU + irinotecan 
Allocated to intervention (n=441) 
Received allocated intervention (n=423) 
Did not receive allocated intervention (n=18) 
Reasons:   Lost files (n=8) 
                 Never starters (n=6) 
Received intervention of 
Group B (n=4) 
Arm B: LV + 5FU 
Allocated to intervention (n=432) 
Received allocated intervention (n=414) 
Did not receive allocated intervention (n=18) 
Reasons:   Lost files (n=6) 
       Never starters (n=8) 
                Received intervention of 
Group A    (n=4) 
Completion (n=350) 
Discontinued intervention (n=77) 
Reasons: Death  (n=3)   
                  Non-fatal toxicity (n=14) 
                  Doctor’s decision (n=4) 
                  Progression (n=5) 
                  Voluntary withdrawal (n=30) 
                  Other (n=16) 
                  Unknown (n=5) 
Completion (n=347) 
Discontinued intervention (n=71) 
Reasons: Death  (n=3)   
                  Non-fatal toxicity (n=10) 
                  Doctor’s decision (n=2) 
                  Progression (n=10) 
                  Voluntary withdrawal (n=31) 
                  Other (n=9) 
                  Unknown (n=6) 
Dead (n=118) 
Still on follow-up (n=311) 
Lost to follow-up* (n=12) 
Dead (n=128) 
Still on follow-up (n=297) 
Lost to follow-up* (n=7) 
Figure 1 Outline of the study. *When followed-up for less than four years.
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treatment discontinuation was voluntary withdrawal
(30 patients in Arm A and 31 patients in Arm B). Addi-
tional reasons for treatment discontinuation were toxi-
city (14 patients in Arm A and 10 patients in Arm B),
disease progression (5 versus 10), death (3 versus 3),
physician’s decision (4 versus 2) and others (16 versus
9). In all, 350 (79%) patients randomized in Arm A and
347 (80%) in Arm B completed treatment.
Efficacy
The median follow-up time was 77.4 months (range, 0.1
to 124.7). There were no significant differences between
irinotecan plus LV plus 5FU and LV plus 5FU in OS
and DFS (Table 2). Survival curves are presented in
Figures 2 and 3. The probability of OS at three years
was 0.88 for patients in Arm A and 0.86 for those in
Arm B, while the five-year OS probability was 0.78 and
0.76 for patients in Arm A and Arm B, respectively.
Furthermore, the probability of DFS at three years was
0.78 and 0.76 for patients in Arm A and Arm B, respec-
tively. Five-year DFS probability was 0.70 for Arm A
and 0.68 for Arm B.
When patients were analyzed by stage (Table 3), those
with Dukes B disease had an OS probability at three
years of 0.93 in Arm A and 0.89 in Arm B, while their
five-year OS probability was 0.86 and 0.83 in Arms A
and B, respectively. Furthermore, the probability of DFS
at three years was 0.86 and 0.83 for patients in Arms A
and B, respectively. The three-year OS probability for
patients with stage C disease was 0.79 in Arm A and
0.82 for those in Arm B, while their five-year OS
Table 1 Patient characteristics
Characteristic Arm A: IRI+LV+5FU
N = 441 (%)
Arm B: LV+5FU
N = 432 (%)
P
Age (years) 0.336
Median 65 65
Range 26 to 79 24 to 79
Sex 0.892
Female 206 (47) 199 (46)
Male 235 (53) 233 (54)
Stage (Dukes) 0.946
B 214 (48) 211 (49)
C 227 (52) 221 (51)
Primary tumor (T) 0.891
T1 and T2 29 (6) 27 (6)
T3 and T4 405 (92) 399 (93)
Unknown 7 (2) 6 (1)
Regional lymph
nodes (N)
0.350
N0 210 (48) 208 (48)
N1 153 (35) 134 (31)
N2 70 (16) 82 (19)
Unknown 8 (2) 8 (2)
Histology grade 0.048
I 40 (9) 47 (11)
II 334 (76) 296 (68)
III 62 (14) 84 (20)
Unknown 5 (1) 5 (1)
Number of lymph
nodes examined
0.354
Median 14 14
Range 0 to 96 0 to 70
Number of lymph
nodes involved*
0.271
Median 2 3
Range 1 to 23 1 to 27
Site of disease 0.640
Cecum 88 (20) 95 (22)
Ascending colon 67 (15) 67 (16)
Transverse colon 29 (7) 30 (7)
Descending colon 36 (8) 44 (10)
Sigmoid 218 (49) 194 (45)
Unknown 4 (1) 2 (0.5)
Perforation 0.897
Yes 406 (92) 398 (92)
No 33 (7) 31 (7)
Unknown 2 (1) 3 (1)
Obstruction 0.277
Yes 386 (88) 365 (84)
No 54 (12) 64 (15)
Unknown 1 (0.2) 3 (1)
*Only for stage C
disease.
Table 2 Disease-free survival and overall survival
Arm A IRI+LV
+5FU
Arm B LV
+5FU
P (log-
rank)
Disease-free survival
(DFS)
0.436
Progressions, n (%) 110 (24.9) 112 (25.9)
Median (months) Not reached yet Not reached
yet
three-year DFS (%) 78 76
five-year DFS (%) 70 68
seven-year DFS (%) 66 63
Overall survival (OS) 0.334
Deaths, n (%) 118 (26.8) 128 (29.6)
Median (months) Not reached yet Not reached
yet
three-year OS (%) 88 86
five-year OS (%) 78 76
seven-year OS (%) 72 69
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tively. DFS probability at three years was 0.69 and 0.68
for patients in Arms A and B, respectively. Only 24
(2.7%) patients out of 873 who were analyzed developed
secondary malignancy (10 in arm A and 14 in arm B).
O u rr e s u l t sd on o tc h a n g ei fw eu s et h ed e f i n i t i o no f
DFS as used in the MOSAIC trial (that is, not including
secondary malignancies) [19].
The median relative dose intensity for 5FU was 0.97
(range 0.24 to 1.27) in Arm A and 0.86 (0.14 to 1.10) in
Arm B (P < 0.001). The relative dose intensity for irino-
tecan in Arm A was 0.95 (range 0.21 to 1.27) (Table 4).
In univariate analysis, the most important prognostic
factors were age at diagnosis as a continuous variable
hazard rate (HR) = 1.03, 95% CI 1.02 to 1.05, P <0 . 0 0 1
for OS and HR = 1.02, 95% CI 1.01 to 1.03, P = 0.001
for DFS), stage C versus B (HR = 2.04, 95% CI 1.57 to
2.65, P < 0.001 for OS and HR = 2.06, 95% CI 1.63 to
2.60, P <0.001 for DFS), T3 and T4 versus T1 and T2
disease (HR = 2.72, 95% CI 1.28 to 5.77, P = 0.009 for
OS and HR = 2.64, 95% CI 1.36 to 5.13, P = 0.004 for
DFS), number of involved lymph nodes as continuous
variable (HR = 1.10, 95% CI 1.08 to 1.13, P <0.001 for
OS and HR = 1.10, 95% CI 1.08 to 1.13, P <0.001 for
DFS), the presence or not of obstruction (HR = 1.35,
95% CI 0.97 to 1.88, P = 0.076 for OS and HR = 1.37,
95% CI 1.01 to 1.85, P = 0.041 for DFS), and the pre-
sence or not of perforation (HR = 1.46, 95% CI 0.95 to
2.52, P = 0.082 for OS and HR = 1.61, 95% CI 1.10 to
2.35, P = 0.013 for DFS).

Figure 2 Kaplan-Meier curves for the DFS in the two groups.
Figure 3 Kaplan-Meier curves for the OS in the two groups.
Table 3 Disease-free survival and overall survival
stratified by stage
Arm A IRI+LV
+5FU
Arm B LV
+5FU
P (log-rank)
Stage B (n = 425)
Disease-free survival
(DFS)
0.561
Progressions, n (%) 36 (16.8) 35 (16.6)
Median (months) Not reached yet Not reached
yet
three-year DFS (%) 86 83
five-year DFS (%) 79 78
seven-year DFS (%) 75 73
Overall survival (OS) 0.389
Deaths, n (%) 39 (18.2) 46 (21.8)
Median (months) Not reached yet Not reached
yet
three-year OS (%) 93 89
five-year OS (%) 86 83
seven-year OS (%) 80 78
Stage C (n = 448)
Disease-free survival
(DFS)
0.515
Progressions, n (%) 74 (32.6) 77 (34.8)
Median (months) 106 104
three-year DFS (%) 69 68
five-year DFS (%) 60 57
seven-year DFS (%) 57 52
Overall survival (OS) 0.539
Deaths, n (%) 79 (34.8) 82 (37.1)
Median (months) Not reached yet Not reached
yet
three-year OS (%) 83 83
five-year OS (%) 71 68
seven-year OS (%) 64 59
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1.03, 95% CI 1.02 to 1.05, P < 0.001), stage (C versus B)
(HR = 1.41, 95% CI 1.04 to 1.92, P = 0.028) and number
of involved lymph nodes (HR = 1.09, 95% CI 1.05 to
1.12, P < 0.001) maintained predictive significance for
OS. Similarly, older age (HR = 1.02, 95% CI 1.01 to
1.03, P = 0.002), stage (C versus B) (HR = 1.44, 95% CI
1.10 to 1.90, P = 0.009), number of involved lymph
nodes (HR = 1.09, 95% CI 1.05 to 1.12, P < 0.001) and
the presence of obstruction (HR = 1.43, 95% CI 1.05 to
1.94, P = 0.022) were found to be significantly associated
with poorer DFS.
Toxicity
Serious adverse events associated with each treatment
regimen are listed in Table 5. Regarding toxicity,
patients were analyzed according to the treatment
patients actually received. With the exception of leuco-
penia and neutropenia, which were higher in patients in
Arm A (P =0 . 0 3 7a n dP < 0.001, respectively), there
were no significant differences in Grades 3 and 4 toxici-
ties between the two regimens. The most frequently
recorded Grade 3/4 toxicity was diarrhea in both treat-
ment arms, followed by neutropenia. Overall, 116
patients in group A (27%) experienced any severe toxi-
city versus 76 patients in group B (18%), P =0 . 0 0 2 .I n
14 (3%) patients on Arm A and 10 (2%) patients on
Arm B, treatment was stopped due to an adverse event.
The unscheduled hospital admissions of patients due to
treatment Grade 3 or 4 toxicity were 39 (9%) in Arm A
and 47 (11%) in Arm B (P = 0.363). Granulocyte col-
ony-stimulating factor (G-CSF) because of leucopenia/
neutropenia was administered in 135 patients, 98 (23%)
in Arm A and 37 (9%) in Arm B (P < 0.001). Of the 246
deaths that occurred during the follow-up period, 241
(98%) were due to colon cancer, 2 due to toxicity of the
treatment (neutropenic sepsis) and 4 due to other
causes such as pulmonary embolism (2 patients), acute
myocardial infarction and CNS ischemia.
Discussion
This study was designed to assess the impact on the
three-year disease-free survival of the addition of irino-
tecan to conventional adjuvant treatment with LV-
modulated bolus 5FU, following curative resection of
stage II or III colon cancer. Based on our experience
with irinotecan’s safety and efficacy [12] and on the
encouraging results of several studies in patients with
metastatic disease [9-14], it was anticipated that irinote-
can would be an effective addition to adjuvant treatment
program for colon cancer. Our study did not demon-
strate a statistically significant difference in the three-
year disease-free and overall survival between the study
arms.
In agreement with our study, three large prospective
randomized trials evaluating the addition of irinotecan
t ob o l u so rc o n t i n u o u si n f u s i o no f5 F Ua n dL Vh a d
failed to show a survival benefit in colon cancer
Table 4 Dose intensity (DI)
Arm A: IRI+LV+5FU
N = 427
Arm B: LV+5FU N
= 418
P
DI of irinotecan
(mg/m
2/wk)
Median 50.5 NA*
Range 11 to 68 NA
Relative DI of
irinotecan
Median 0.95 NA
Range 0.21 to 1.27 NA
DI of LV (mg/m
2/
wk)
<
0.001
Median 129 131
Range 32 to 165 21 to 279
Relative DI of LV
Median 0.96 0.87
Range 0.24 to 1.24 0.14 to 1.86
DI of 5FU
(mg/m
2/wk)
<
0.001
Median 291 322
Range 73 to 380 54 to 411
Relative DI of 5FU
Median 0.97 0.86
Range 0.24 to 1.27 0.14 to 1.10
*Not applicable.
Table 5 Incidence of Grades 3 and 4 toxicities (treatment
as administered)
Arm A: IRI+LV+5FU
(N = 427)
Arm B: LV+5FU
(N = 418)
n (%) n (%)
Grade 3 Grade 4 Grade 3 Grade 4
Leukopenia 10 (2) 0 2 (0.5) 0
Neutropenia 39 (9) 6 (1) 7 (2) 4 (1)
Anemia 2 (0.5) 0 0 0
Thrombocytopenia 2 (0.5) 0 0 0
Diarrhea 58 (14) 6 (1) 52 (12) 2 (0.5)
Nausea/vomiting 7 (2) 0 1 (0.2) 0
Alopecia 6 (1) 0 1 (0.2) 0
Neutropenic fever 4 (1) 0 1 (0.2) 0
Constipation 2 (0.5) 0 1 (0.2) 0
Pain 1 (0.2) 0 2 (0.5) 0
Hepatotoxicity 1 (0.2) 0 2 (0.5) 0
Mucositis 0 0 2 (0.5) 0
Fatigue 1 (0.2) 0 0 0
Watery eye 0 0 1 (0.2) 0
Peripheral neuropathy 0 0 1 (0.2) 0
Skin 0 0 1 (0.2) 0
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compared conventional bolus 5FU plus LV with or with-
out addition of irinotecan [20]. After resection of stage
III colon cancer, 1,264 patients were assigned randomly
to receive a conventional regimen (weekly LV 500 mg/
m
2 plus 5FU 500 mg/m
2, administered for six consecu-
tive weeks followed by two weeks of rest, for four
cycles) or the experimental IFL regimen (weekly irinote-
can 125 mg/m
2 and LV 20 mg/m
2 plus 5FU 500 mg/m
2,
administered for four consecutive weeks followed by
two weeks of rest, for five cycles). Lethal and nonlethal
toxicity was significantly greater for IFL than for LV
plus 5FU. On the other hand, no differences were found
at three years for IFL compared with LV plus 5FU in
the probability of overall survival, disease-free survival,
or relapse-free survival; similarly, no differences were
seen in five-year outcomes.
The negative results of CALGB 89803 are mirrored
in two recently published European adjuvant trials of
irinotecan plus continuous infusion 5FU (FOLFIRI),
which failed to lengthen disease-free survival in colon
cancer after surgical resection: PETACC-3 and
A C C O R D .M o r es p e c i f i c a l l y ,t h eP E T A C C - 3s t u d y
investigated whether the addition of irinotecan to the
de Gramont infusional 5FU and LV adjuvant regimen
(LV5FU2) would improve DFS in patients with stage
III colon cancer. The principal efficacy analysis was
based on 2,094 treated patients, randomly allocated in
the LV5FU2 strata. Severe gastrointestinal and hemato-
logic toxicity was increased in patients receiving irino-
tecan [21]. The multicenter adjuvant phase III trial
published by Ychou et al. evaluated the addition of iri-
notecan to LV5FU2 in colon cancer patients specifi-
cally at high risk of relapse [22]. This study randomly
assigned 400 patients with either N1 tumors with
obstruction/perforation or N2 tumors to LV5FU2, with
or without irinotecan. Similarly, there was no evidence
of improvement in DFS and OS in patients receiving
irinotecan, while higher rates of Grades 3 and 4 neu-
tropenia were observed.
Our study was designed to include both stage II and
III patients in the analysis. Although historically many
studies have combined the population of patients with
both stage II and stage III disease, including some irino-
tecan adjuvant trials, the current trend is to perform
separate clinical trials, since there are significant survival
differences among patients with different T and N sta-
tus. Some trials have been designed with a particular
focus on high risk patients. Unfortunately, when high
risk patients were evaluated, such as in the ACCORD
study, as previously mentioned, irinotecan still did not
provide significant benefit compared to 5FU and LV.
In the present study, we utilized a weekly IFL regimen
based on our previous experience. More specifically,
Kalofonos et al. [12] treated 55 patients with first-line che-
motherapy for advanced disease with either irinotecan 80
mg/m
2 (7 patients) or 70 mg/m
2 (48 patients) plus LV 200
mg/m
2 and 5FU 450 mg/m
2, weekly for six weeks followed
by a two-week rest period. Treatment was continued for
four cycles. Because of Grades 3 and 4 diarrhea in four of
the first seven patients, the study was amended to reduce
the starting dose of irinotecan from 80 to 70 mg/m
2
weekly. In another randomized phase II trial conducted by
our Cooperative Group, 295 patients with metastatic col-
orectal cancer were randomized to receive as first-line
chemotherapy either irinotecan 70 mg/m
2 plus LV and
5FU, as previously described, or oxaliplatin plus LV plus
5FU. Severe diarrhea occurred in 12.3% of patients of the
irinotecan arm [17]. Hematological toxicity and gastroin-
testinal mucositis were a concern when the regimen in the
experimental arm was designed because of our previous
experience and data provided by Saltz et al. [16] on Grade
3 or 4 neutropenia and diarrhea in 53.8% and 22.7% of
patients, respectively, who were treated with IFL for meta-
static colon cancer. Therefore, we employed irinotecan at
a relatively low dose of 80 mg/m
2 with LV 200 mg/m
2 and
5FU 450 mg/m
2, weekly for four instead of six weeks, fol-
lowed by the rest period. This dose of irinotecan was sub-
stantially reduced in comparison with the dose of 125 mg/
m
2 which was utilized by Saltz et al. [20] in their adjuvant
IFL regimen. On the other hand, treatment in Arm B was
administered weekly for six consecutive weeks followed by
the rest period that has resulted in combination with an
increased by 10% 5FU dose in a statistically greater relative
dose intensity for the fluoropyrimidine (0.97 vs.0 . 8 6 ,P
<0.001). However, these differences are unlikely to have
any impact on efficacy.
With the exception of leucopenia and neutropenia,
which were higher in patients in Group A, there were
no other significant differences in Grades 3 and 4 toxici-
ties between the two regimens. The most frequently
recorded Grade 3/4 toxicity was diarrhea in both treat-
ment arms, followed by neutropenia. More specifically,
severe diarrhea was observed in 15% and 12.5% of
patients in Group A and Group B, respectively, while
the corresponding rates for patients treated with either
I F Lo rL Vp l u s5 F Ui nt h eC A L G B8 9 8 0 3s t u d yw e r e
31% and 35%, respectively. On the other hand, Grade 3/
4 neutropenia of the irinotecan plus LV plus 5FU arm
was similar to that reported by Saltz et al. [20]. In this
latter study, a higher incidence of treatment-related
deaths has been reported with the IFL regimen com-
pared to LV plus 5FU. However, in the present study
this increased incidence was not observed in the experi-
mental arm, possibly due to the dose level of irinotecan.
Because of the higher incidence of severe neutropenia,
more G-CSF was administered in patients who were
allocated to irinotecan-based chemotherapy arm.
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Page 8 of 10Based on the results of the present and three previous
negative trials [20-22], irinotecan should not be used in
the adjuvant setting, because it adds no benefit when
combined with either bolus or continuous-infusion 5FU.
The question of why irinotecan has failed to demon-
strate an advantage in the adjuvant setting while oxali-
platin is clearly of benefit still remains unanswered.
Possible explanations involve clinical and pharmacologic
aspects. Although the two head-to-head comparisons of
infusional 5FU, LV, and oxaliplatin (FOLFOX) and infu-
sional 5FU, LV, and irinotecan (FOLFIRI) in metastatic
disease [23,24] failed to show a significant difference in
progression-free survival, each of these studies was
remarkably underpowered to rule out a clinically mean-
ingful difference between these regimens. Thus, the lack
of adequately powered head-to-head comparisons
between FOLFOX and FOLFIRI leaves open the possibi-
lity that FOLFOX may be superior to FOLFIRI [6].
In the PETACC-3 trial, the patients enrolled in the iri-
notecan arm experienced more dose reductions and more
treatment discontinuation because of toxicity compared
with the LV5FU2 arm. On the other hand, in this study
after adjustment for imbalances in the TNM status
between treatment groups, a multivariate analysis “ren-
dered” a statistically significant DFS advantage in favor of
the irinotecan arm (P = 0.021), while a highly significant
relapse-free survival advantage for the same arm could be
achieved (P = 0.009) [21]. Furthermore, the concept of
individualized therapy based on prognostic and predictive
molecular markers to better select patients who would
benefit from a specific intervention is likely to be integral.
Therefore, the possibility that irinotecan combined with
LV and 5FU might be effective as adjuvant therapy in cer-
tain subsets of patients with colon cancer defined by var-
ious markers seems to be reasonable [6,25]. In this
context, we have retrospectively analyzed by immunohis-
tochemistry paraffin-embedded tumor tissues for detection
of thymidylate synthase and topoisomerase I in patients
treated with adjuvant chemotherapy within HeCOG pro-
tocols and we found that those expressing topoisomerase I
seem to benefit from irinotecan-containing adjuvant che-
motherapy [26]. Of particular interest is the CALGB
89803 study [20] that did not show, as previously men-
tioned, any differences in survival outcomes between IFL
arm and LV plus 5FU arm. However, loss of tumor DNA
mismatch repair (MMR) function could predict improved
five-year DFS in patients treated with the IFL regimen as
compared with those receiving LV plus 5FU [27]. Since
the subset of patients who could derive a benefit from
adjuvant irinotecan seems to represent a relatively small
fraction, it is unlikely to be recognized when different
populations are analyzed together. Finally, another specu-
lation why irinotecan does not work in the adjuvant set-
ting is the possibility that metastatic colon cancers may
have different biological characteristics compared to pri-
mary tumors that could explain greater efficacy of irinote-
can in metastatic disease.
Conclusions
The results of our trial demonstrated that weekly bolus
irinotecan plus LV plus 5FU should not be used in the
adjuvant setting for colon cancer. Since the number of
agents that are potentially effective in the systemic treat-
ment of completely resected stage II or III disease is
increasing, it is important to ascertain which subgroups
of patients will benefit from a specific treatment.
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